Related references
Note: Only part of the references are listed.Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease Indacaterol Versus Tiotropium
James F. Donohue et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Anticholinergic Drugs for the Treatment of COPD Are Safe ... Are They?
Klaus F. Rabe
CHEST (2010)
Cardiovascular Safety of Tiotropium in Patients With COPD
Bartolome Celli et al.
CHEST (2010)
Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients
C. Verkindre et al.
RESPIRATORY MEDICINE (2010)
Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms
J. A. van Noord et al.
RESPIRATORY MEDICINE (2010)
Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients
C. Vogelmeier et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2010)
The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD
Mario Cazzola et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2010)
Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD
Ronald Dahl et al.
THORAX (2010)
Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD
Donald P. Tashkin et al.
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2009)
Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review
Nicholas C. Ray et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
Safety of long-acting β-agonists in stable COPD -: A systematic review
Gustavo J. Rodrigo et al.
CHEST (2008)
Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD
Klaus F. Rabe et al.
CHEST (2008)
Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease - A systematic review and meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial
Donald P. Tashkin et al.
RESPIRATORY MEDICINE (2008)
Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study
Claus Vogelmeier et al.
RESPIRATORY MEDICINE (2008)
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison
Stephen Rennard et al.
RESPIRATORY MEDICINE (2008)
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease - A randomized trial
Shawn D. Aaron et al.
ANNALS OF INTERNAL MEDICINE (2007)
Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD:: A 28-day randomised, placebo controlled clinical trial
Jutta Beier et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2007)
Tiotropium for the treatment of stable chronic obstructive pulmonary disease: A systematic review with meta-analysis
Gustavo J. Rodrigo et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2007)
Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
JA van Noord et al.
CHEST (2006)
Addition of formoterol to tiotropium produces better FEV1 and FVC responses when measured over 24 hours following single-dose administration in subjects with moderate-to-severe COPD
B Brashier et al.
CHEST (2005)
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
JA van Noord et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients
M Cazzola et al.
RESPIRATORY MEDICINE (2005)
The functional impact of adding salmeterol and tiotropium in patients with stable COPD
M Cazzola et al.
RESPIRATORY MEDICINE (2004)
Cardiovascular effects of β-agonists in patients with asthma and COPD -: A meta-analysis
SR Salpeter et al.
CHEST (2004)
Cardiovascular safety of salmeterol in COPD
GT Ferguson et al.
CHEST (2003)
Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus
B Sarria et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2002)
Share Paper
